購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
huHSC-NKG-ProF Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huHSC-NKG-ProF Mouse
製品名
huHSC-NKG-ProF Mouse
製品ID
C001543
系統名
huHSC-ProF-NOD.Cg-PrkdcscidIl2rgem1cya/Cya
背景情報
NKG
状況
このマウス系統を論文で使用する場合は、「huHSC-NKG-ProF Mouse（カタログ番号C001543）はサイアジェンから購入しました。」と引用してください。
Immunodeficient Mice
Humanized Immune System Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Immunodeficient Mice
Humanized Immune System Models
基本情報
検証 Data
関連リソース
基本情報
遺伝子名
遺伝子別名
gc, p64, [g]c, CD132, gamma(c)
NCBI ID
染色体
Chr X
MGI ID
--
さらに
系統詳細
NKG mice (Catalog number: C001316) are a kind of severe immunodeficient mice generated by Cyagen through deleting the Il2rg gene from NOD-Scid mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for the transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenograft (PDX).
huHSC-NKG mice are immune system humanized mouse models constructed by transplanting human hematopoietic stem cells (HSC) into NKG mice after sub-lethal dose irradiation. This model has a long lifespan and can successfully reconstitute various immune cells. In addition, huHSC-NKG mice typically do not develop graft-versus-host disease (GvHD) and the reconstitution period can be long.
The huHSC-NKG-ProF mouse is the latest enhanced version of the huHSC-NKG series, where "Pro" indicates the enhanced series and "F" indicates full immune reconstitution. This mouse model uses advanced neonatal techniques optimised to develop a variety of human immune cells, including lymphoid T cells, B cells and NK cells, as well as myeloid dendritic cells (DCs), monocytes, macrophages and granulocytes. Due to its ability to reconstitute multiple types of human-derived immune cells, the huHSC-NKG-ProF mouse is also referred to as a fully humanised immune system mouse. It is an ideal model for immunological research, antibody-dependent cellular cytotoxicity (ADCC) studies and the development of tumor vaccines, cellular therapies and other biopharmaceuticals.
適用分野
Tumor Immunology Research: Development of drugs such as immune checkpoint inhibitors, tumor vaccines, allogeneic cell therapies, and oncolytic viruses, as well as investigations into mechanisms that reverse T cell exhaustion, antibody-dependent cellular cytotoxicity (ADCC), and tumor-specific immunity；
Autoimmune Disease Research: Evaluation of the mechanisms underlying the onset of autoimmune diseases and the exploration of therapeutic strategies；
Drug Metabolism and Toxicity Research: Assessment of candidate compounds' pharmacokinetic properties and toxic effects in vivo.
検証 Data
1. Survival and Growth Curves
Figure 1. Survival and body weight changes in NKG mice following human hematopoietic stem cells (HSCs) transplantation.
2. Reconstitution of Human Leukocytes in Peripheral Blood
Human cord blood-derived HSCs were transplanted into NKG mice for human immune system reconstitution. Once the reconstitution stabilized, the proportion of human CD45+ leukocytes reached approximately 40%-60%.
Figure 2. Reconstitution of human CD45+ leukocytes in the peripheral blood of NKG mice following transplantation of human HSCs.
3. Reconstitution of Human T Cells and B Cells in Peripheral Blood
T cell reconstitution began by week 10 post-transplantation, with average T cell levels reaching 50% by week 14. The average proportion of B cells was approximately 10%-20%.
Figure 3. Reconstitution of human T cells and B cells in the peripheral blood of NKG mice following transplantation of human HSCs*.
*Based on our internal testing, there may be variations in T cell reconstitution times depending on the HSC donor. Following process optimization, T cells can generally be reconstituted by week 10 and stabilized by week 14 after the transplantation of most HSC donors.
*Based on our internal testing, there may be variations in T cell reconstitution times depending on the HSC donor. Following process optimization, T cells can generally be reconstituted by week 10 and stabilized by week 14 after the transplantation of most HSC donors.
4. Reconstitution of Human NK Cells and Monocytes in Peripheral Blood
The average reconstitution proportion of NK cells remained between 20%-40%, while monocyte reconstitution in peripheral blood was observed at 1%-3%, with a higher proportion in the spleen (see spleen data section).
Figure 4. Reconstitution of human NK cells and monocytes in the peripheral blood of NKG mice following transplantation of human HSCs.
5. Proportion and Subtypes of Humanized Immune Cells in the Spleen After 14 Weeks of Reconstitution
Spleen tissues were collected 14 weeks after transplantation of human cord blood-derived HSCs into NKG mice, and the proportion and subtypes of humanized immune cells were analyzed. Results indicated that the average proportion of humanized immune cells reached 50%, with T cells comprising 40%-50% of the total human immune cells, B cells approximately 20% (higher than that in peripheral blood), NK cells around 20%, and total myeloid cells making up 20%-25% (also higher than in peripheral blood).
Figure 5. Proportion and subtypes of humanized immune cells in the spleen.
6. Subtype Analysis of Myeloid Cells in the Spleen After 14 Weeks of Reconstitution
Spleen tissues were collected 14 weeks after transplantation of human cord blood-derived HSCs into NKG mice for myeloid cell subtype analysis. Results showed that various myeloid subtypes were reconstituted, including granulocytes, different types of monocytes (Classical, Intermediate, Nonclassical), and macrophages (M1-macrophage, M2-macrophage). In the absence of tumors, M1-macrophages were more prevalent, but polarization towards M2-macrophages may occur with tumor progression. Classical dendritic cells (cDC) constituted 7% of total myeloid cells, providing a foundation for antigen processing and presentation.
Figure 6. Subtype analysis of myeloid cells in the spleen.
7. Application Cases
（1）mRNA Tumor Vaccine Treatment for Melanoma A375
Following treatment with the mRNA tumor vaccine, the tumor suppression rate for melanoma A375 reached 38.75%. In antigen-specific T cell assays, the vaccine treatment group exhibited significantly increased proportions of tetramer and IFN-γ, indicating the presence of functional human T cells and dendritic cells in the huHSC-NKG-ProF mice model, which may serve as an effective tool for preclinical tumor vaccine efficacy studies.
Figure 7. A case study using huHSC-NKG-ProF mice for mRNA tumor vaccine development.
（2）Rituximab Treatment for Burkitt’s Lymphoma Raji
Following four treatments with Rituximab, the tumor suppression rate reached 77%, demonstrating significant efficacy and indicating the presence of functional human NK cells in the huHSC-NKG-ProF mice.
Figure 8. A case study using huHSC-NKG-ProF mice for antibody drug development.
（3）Autoimmune Disease-Colitis Model
In this experiment, C57BL/6 and huHSC-NKG-ProF mice were fed 3% DSS. After 7 days, similar colitis phenotypes, including ulcers, intestinal mucosal damage, tissue edema and congestion, and glandular structure disruption, were observed in both huHSC-NKG-ProF and C57BL/6 mice, indicating that huHSC-NKG-ProF mice can be utilized to construct humanized colitis models.
Figure 9a. A case study using huHSC-NKG-ProF mice to establish a humanized colitis model.
Figure 9b. A case study using huHSC-NKG-ProF mice to establish a humanized colitis model.
関連リソース
お問い合わせ
ご不明な点やご質問などございましたら、お気軽にお問い合わせください。担当スタッフがサポートさせていただきます。下記のフォームにご記入いただければ、1〜2営業日以内に折り返しご連絡いたします。
Related Product
All Related ProductsResources
Publications
Cell Metabolism
2025-06-03
Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming
続きを読む
Cell Metabolism
2025-05
Foxp3 conferslong-term efficacyof chimeric antigenreceptor-T cells via metabolic reprogramming
続きを読む
Cellular & Molecular Immunology
2026-06-21
Acquisition of Vimentin by trogocytosis inhibits the NK cell-mediated immune response against circulating tumour cells (CTCs)
続きを読む
Gut
2025-02-26
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
続きを読む
Cancer Research
2026-02-11
SAICAR Drives T Regulatory Cell Differentiation and FOXP3 Maintenance to Promote Immunotherapy Resistance
続きを読む
CANCER RESEARCH
2026-02-10
SAICAR Drives T Regulatory Cell Differentiation and FOXP3 Maintenance to Promote Immunotherapy Resistance
続きを読む
Nature Communications
2026-01-18
Palmitic acid-triggered B7H3 palmitoylation promotes immune escape
続きを読む
Nature Communications
2026-02-03
Escherichia coli promotes colorectal cancer metastasis by maintaining enhancer-promoter loops through releasing neutrophil extracellular traps
続きを読む
Nature Communications
2026-02-02
Escherichia coli promotes colorectal cancer metastasis by maintaining enhancer-promoter loops through releasing neutrophil extracellular traps
続きを読む
Nature Communications
2026-01-19
Palmitic acid-triggered B7H3 palmitoylation promotes immune escape
続きを読む
Cell Reports Medicine
2025-02-24
An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α1/2 shedding
続きを読む
Cell Reports Medicine
2025-03-17
An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B a1/2 shedding
続きを読む
Journal of Nanobiotechnology
2025-04-21
PTEN as a prognostic factor for radiotherapy plus immunotherapy response in nasopharyngeal carcinoma
続きを読む
Cell Death & Disease
2026-01-23
RNASEH2C enhances TRAF3IP1 to degrade RAI14 in lysosomes thus hindering macrophage antigen presentation and advancing liver cancer
続きを読む
Cell Death & Disease
2026-01-22
RNASEH2C enhances TRAF3IP1 to degrade RAI14 in lysosomes thus hindering macrophage antigen presentation and advancing liver cancer
続きを読む
Cell Genomics
2025-07-17
Oncogenic roles of young human de novo genes and their potential as neoantigens in cancer immunotherapy
続きを読む
Cell Genomics
2025-07-16
Oncogenic roles of young human de novo genes and their potential as neoantigens in cancer immunotherapy
続きを読む
Gut
2025-02-27
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
続きを読む
Research Square
2025-07-31
Acquisition of Vimentin by trogocytosis inhibits the
NK cell-mediated immune response against CTCs
続きを読む
Research Square
2025-07-30
Acquisition of Vimentin by trogocytosis inhibits the NK cell-mediated immune response against CTCs
続きを読む
Items: 1 to 5 of 20
1
2
3
4
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。